Clotrimazole Shows Promise in Improving NSCLC Survival

Preclinical data has suggested antifungal azole derivatives have antitumor efficacy that might modulate response to immune checkpoint inhibitors (ICIs). A new study evaluated the association of azole drugs with overall survival (OS) in a population of patients with non-small cell lung cancer (NSCLC) treated with ICI within the VHA.

Multiple Comorbidities Affect NSCLC Survival in Older Veterans

Most advanced non-small cell lung cancer (NSCLC) patients are older adults, and they often have multiple other comorbidities (multimorbidity) when initiating treatment. A new study sought to learn more about the nature and impact of multimorbidity, especially since aging patients are often excluded from clinical trials.